Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market

Group 1 - Vertex Pharmaceuticals (VRTX) stock decreased by 1.68% to $440.87, underperforming the S&P 500 which fell by 0.22% [1] - Over the past month, Vertex shares increased by 3.31%, outperforming the Medical sector's 0% change and the S&P 500's 0.45% gain [1] Group 2 - The upcoming earnings report for Vertex is expected to show an EPS of $4.24, a 133.05% increase year-over-year, with revenue anticipated at $2.88 billion, an 8.85% rise compared to the previous year [2] - For the full year, analysts project earnings of $17.82 per share and revenue of $11.91 billion, reflecting increases of 4142.86% and 8.06% respectively from last year [3] Group 3 - Recent changes in analyst estimates indicate a positive outlook for Vertex Pharmaceuticals, suggesting an improving business trend [4] - The Zacks Rank system, which reflects these estimate changes, currently rates Vertex Pharmaceuticals as 3 (Hold) [6] Group 4 - Vertex Pharmaceuticals has a Forward P/E ratio of 25.17, which is higher than the industry average Forward P/E of 19.86 [7] - The Medical - Biomedical and Genetics industry, to which Vertex belongs, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [7]